Clinical Report: Utilizing Digital Tools for Symptom Management in Advanced Cancer
Overview
This randomized study evaluates the impact of an app-facilitated symptom monitoring intervention on health-related quality of life (HRQOL) and acute hospital utilization among patients with advanced cancer receiving palliative care.
Background
Patients with advanced cancer often face significant symptom burdens that adversely affect their quality of life and lead to increased healthcare utilization. Traditional symptom assessment methods may overlook critical symptom exacerbations occurring between scheduled visits. Digital symptom-monitoring interventions have shown promise in improving patient-reported outcomes.
Data Highlights
No numerical data provided in the source material.
Key Findings
The study involved patients aged 18 and older with advanced solid malignant neoplasms not pursuing further systemic treatment.
Participants were randomly assigned to receive either app-facilitated symptom monitoring plus usual care or usual care alone.
The Integrated Palliative Outcome Scale (IPOS) was utilized to assess multidimensional symptom burden.
Caregivers could serve as proxy reporters for participants unable to use the app independently.
The trial aimed to evaluate the intervention's effect on HRQOL, self-efficacy, functional status, and acute hospital utilization.
Clinical Implications
The integration of digital tools in palliative care may facilitate better symptom management and communication between patients and healthcare providers. This approach could lead to improved patient outcomes and reduced reliance on acute care services.
Conclusion
The study highlights the potential benefits of digital symptom monitoring in enhancing the quality of life for patients with advanced cancer receiving palliative care. Further research is needed to confirm these findings and explore broader applications.
by Wing-Lok Chan, Inda Sung Soong, Mei-Ying Lim, Winnie Wing-Yan Tin, Steven Wai-Kwan Siu, Jeffrey Ng, Carmen Leung, Alex Leung, Yin-Ling Tai, Ching-Mei Lam, Li-Yu Hou, Raymond Lo, Victor Ho-Fun Lee, Kwok-Keung Yuen, Dora Kwong, Rina Hui
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
